179 related articles for article (PubMed ID: 15367699)
1. Disulfiram inhibits activating transcription factor/cyclic AMP-responsive element binding protein and human melanoma growth in a metal-dependent manner in vitro, in mice and in a patient with metastatic disease.
Brar SS; Grigg C; Wilson KS; Holder WD; Dreau D; Austin C; Foster M; Ghio AJ; Whorton AR; Stowell GW; Whittall LB; Whittle RR; White DP; Kennedy TP
Mol Cancer Ther; 2004 Sep; 3(9):1049-60. PubMed ID: 15367699
[TBL] [Abstract][Full Text] [Related]
2. Combination therapy targeting the tumor microenvironment is effective in a model of human ocular melanoma.
Mangiameli DP; Blansfield JA; Kachala S; Lorang D; Schafer PH; Muller GW; Stirling DI; Libutti SK
J Transl Med; 2007 Jul; 5():38. PubMed ID: 17640369
[TBL] [Abstract][Full Text] [Related]
3. Disulfiram combined with copper inhibits metastasis and epithelial-mesenchymal transition in hepatocellular carcinoma through the NF-κB and TGF-β pathways.
Li Y; Wang LH; Zhang HT; Wang YT; Liu S; Zhou WL; Yuan XZ; Li TY; Wu CF; Yang JY
J Cell Mol Med; 2018 Jan; 22(1):439-451. PubMed ID: 29148232
[TBL] [Abstract][Full Text] [Related]
4. KINK-1, a novel small-molecule inhibitor of IKKbeta, and the susceptibility of melanoma cells to antitumoral treatment.
Schön M; Wienrich BG; Kneitz S; Sennefelder H; Amschler K; Vöhringer V; Weber O; Stiewe T; Ziegelbauer K; Schön MP
J Natl Cancer Inst; 2008 Jun; 100(12):862-75. PubMed ID: 18544741
[TBL] [Abstract][Full Text] [Related]
5. A Phase 1 dose-escalation study of disulfiram and copper gluconate in patients with advanced solid tumors involving the liver using S-glutathionylation as a biomarker.
Kelley KC; Grossman KF; Brittain-Blankenship M; Thorne KM; Akerley WL; Terrazas MC; Kosak KM; Boucher KM; Buys SS; McGregor KA; Werner TL; Agarwal N; Weis JR; Sharma S; Ward JH; Kennedy TP; Sborov DW; Shami PJ
BMC Cancer; 2021 May; 21(1):510. PubMed ID: 33957901
[TBL] [Abstract][Full Text] [Related]
6. Anticancer imidazoacridinone C-1311 inhibits hypoxia-inducible factor-1α (HIF-1α), vascular endothelial growth factor (VEGF) and angiogenesis.
Paradziej-Łukowicz J; Skwarska A; Peszyńska-Sularz G; Brillowska-Dąbrowska A; Konopa J
Cancer Biol Ther; 2011 Oct; 12(7):586-97. PubMed ID: 21775820
[TBL] [Abstract][Full Text] [Related]
7. Targeting the ATF-1/CREB transcription factors by single chain Fv fragment in human melanoma: potential modality for cancer therapy.
Jean D; Bar-Eli M
Crit Rev Immunol; 2001; 21(1-3):275-86. PubMed ID: 11642609
[TBL] [Abstract][Full Text] [Related]
8. The value of proteasome inhibition in cancer. Can the old drug, disulfiram, have a bright new future as a novel proteasome inhibitor?
Cvek B; Dvorak Z
Drug Discov Today; 2008 Aug; 13(15-16):716-22. PubMed ID: 18579431
[TBL] [Abstract][Full Text] [Related]
9. A Key role for cyclic AMP-responsive element binding protein in hypoxia-mediated activation of the angiogenesis factor CCN1 (CYR61) in Tumor cells.
Meyuhas R; Pikarsky E; Tavor E; Klar A; Abramovitch R; Hochman J; Lago TG; Honigman A
Mol Cancer Res; 2008 Sep; 6(9):1397-409. PubMed ID: 18819928
[TBL] [Abstract][Full Text] [Related]
10. Interleukin 10 suppresses tumor growth and metastasis of human melanoma cells: potential inhibition of angiogenesis.
Huang S; Xie K; Bucana CD; Ullrich SE; Bar-Eli M
Clin Cancer Res; 1996 Dec; 2(12):1969-79. PubMed ID: 9816156
[TBL] [Abstract][Full Text] [Related]
11. Disulfiram induces apoptosis in human melanoma cells: a redox-related process.
Cen D; Gonzalez RI; Buckmeier JA; Kahlon RS; Tohidian NB; Meyskens FL
Mol Cancer Ther; 2002 Jan; 1(3):197-204. PubMed ID: 12467214
[TBL] [Abstract][Full Text] [Related]
12. 3,3',4,4',5,5'-hexahydroxystilbene impairs melanoma progression in a metastatic mouse model.
Paulitschke V; Schicher N; Szekeres T; Jäger W; Elbling L; Riemer AB; Scheiner O; Trimurtulu G; Venkateswarlu S; Mikula M; Swoboda A; Fiebiger E; Gerner C; Pehamberger H; Kunstfeld R
J Invest Dermatol; 2010 Jun; 130(6):1668-79. PubMed ID: 19956188
[TBL] [Abstract][Full Text] [Related]
13. Disulfiram mediated anti-tumour effect in pituitary neuroendocrine tumours by inducing cuproptosis.
Huang N; Feng Y; Liu Y; Zhang Y; Liu L; Zhang B; Zhang T; Su Z; Xue L; Wu ZB
Int Immunopharmacol; 2024 Jun; 134():112159. PubMed ID: 38692018
[TBL] [Abstract][Full Text] [Related]
14. Inhibitory effect of Disulfiram/copper complex on non-small cell lung cancer cells.
Duan L; Shen H; Zhao G; Yang R; Cai X; Zhang L; Jin C; Huang Y
Biochem Biophys Res Commun; 2014 Apr; 446(4):1010-6. PubMed ID: 24657266
[TBL] [Abstract][Full Text] [Related]
15. Disulfiram facilitates intracellular Cu uptake and induces apoptosis in human melanoma cells.
Cen D; Brayton D; Shahandeh B; Meyskens FL; Farmer PJ
J Med Chem; 2004 Dec; 47(27):6914-20. PubMed ID: 15615540
[TBL] [Abstract][Full Text] [Related]
16. Disulfiram induces copper-dependent stimulation of reactive oxygen species and activation of the extrinsic apoptotic pathway in melanoma.
Morrison BW; Doudican NA; Patel KR; Orlow SJ
Melanoma Res; 2010 Feb; 20(1):11-20. PubMed ID: 19966593
[TBL] [Abstract][Full Text] [Related]
17. Disulfiram when Combined with Copper Enhances the Therapeutic Effects of Temozolomide for the Treatment of Glioblastoma.
Lun X; Wells JC; Grinshtein N; King JC; Hao X; Dang NH; Wang X; Aman A; Uehling D; Datti A; Wrana JL; Easaw JC; Luchman A; Weiss S; Cairncross JG; Kaplan DR; Robbins SM; Senger DL
Clin Cancer Res; 2016 Aug; 22(15):3860-75. PubMed ID: 27006494
[TBL] [Abstract][Full Text] [Related]
18. The anthelmintic flubendazole blocks human melanoma growth and metastasis and suppresses programmed cell death protein-1 and myeloid-derived suppressor cell accumulation.
Li Y; Acharya G; Elahy M; Xin H; Khachigian LM
Cancer Lett; 2019 Sep; 459():268-276. PubMed ID: 31128215
[TBL] [Abstract][Full Text] [Related]
19. Oxidative stress and c-Jun-amino-terminal kinase activation involved in apoptosis of primary astrocytes induced by disulfiram-Cu(2+) complex.
Chen SH; Liu SH; Liang YC; Lin JK; Lin-Shiau SY
Eur J Pharmacol; 2001 Mar; 414(2-3):177-88. PubMed ID: 11239917
[TBL] [Abstract][Full Text] [Related]
20. Repurposing Disulfiram as An Anti-Cancer Agent: Updated Review on Literature and Patents.
Ekinci E; Rohondia S; Khan R; Dou QP
Recent Pat Anticancer Drug Discov; 2019; 14(2):113-132. PubMed ID: 31084595
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
